Metastatic Colon Cancer, Metastatic Colorectal Cancer
Conditions
Keywords
colon, colorectal, mcrc, crc, metastatic colon, metastatic colorectal, VEGF, VEGFR
Brief summary
This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.
Detailed description
This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib in combination with BSC versus placebo in combination with BSC in metastatic colorectal cancer participants who have progressed on, or were intolerant to, chemotherapy, anti-VEGF and anti-EGFR biologics, and TAS-102 or regorafenib. Participants with MSI-H/MMR deficient tumors must have also received an immune checkpoint inhibitor if approved and available and if deemed appropriate. Subjects with BRAF-mutant tumors must have been treated with a BRAF inhibitor if approved and available and if deemed appropriate. Metastatic colorectal cancer cannot be cured by surgery. Therefore, treatment principals are primarily aimed at controlling disease progression and prolonging survival. Standard first- and second-line therapy includes cytotoxic drugs such as 5-fluorouracil, oxaliplatin, and irinotecan; anti-VEGF therapy; and, if RAS wild type, anti-EGFR therapy. After the first two lines of chemotherapy, standard third-line treatment is either TAS-102 or regorafenib. There are currently no effective treatments for patients who have progressed on standard, approved therapies, and treatment options include reuse of prior therapies, clinical trials or BSC. Consequently, there is an unmet medical need for additional safe and effective treatment.
Interventions
DRUGFruquintinib
Oral VEGFR inhibitor
DRUGPlacebo
Placebo capsule
Sponsors
Hutchison Medipharma Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provide written informed consent; * Age ≥18 years; * Histologically and/or cytologically documented metastatic colorectal adenocarcinoma. RAS, BRAF, and microsatellite instability microsatellite instability (MSI)/mismatch repair (MMR) status for each patient must be documented, according to country level guidelines; * Participants must have progressed on or been intolerant to treatment with either trifluridine/tipiracil (TAS-102) or regorafenib. Participants are considered intolerant to TAS-102 or regorafenib if they have received at least 1 dose of either agents and were discontinued from therapy for reasons other than disease progression. Participants who have been treated with both TAS-102 and regorafenib are permitted. Participants must also have been previously treated with standard approved therapies: fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-EGFR therapy; * Participants with microsatellite-high (MSI-H) or mismatch repair deficient (dMMR) tumors must have been treated with immune checkpoint inhibitors if approved and available in the participant's country unless the patient is ineligible for treatment with a checkpoint inhibitor; * Participants who received oxaliplatin in the adjuvant setting and developed metastatic disease during or within 6 months of completing adjuvant therapy are considered eligible without receiving oxaliplatin in the metastatic setting. Participants who developed metastatic disease more than 6 months after completion of oxaliplatin-containing adjuvant treatment must be treated with oxaliplatin-based therapy in the metastatic setting to be eligible; * Body weight ≥40kg; * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; * Have measurable disease according to RECIST Version 1.1, assessed locally. Tumors that were treated with radiotherapy are not measurable per RECIST Version 1.1, unless there has been documented progression of those lesions; * Expected survival \>12 weeks. * For female participants of childbearing potential and male participants with partners of childbearing potential, agreement to use a highly effective form(s) of contraception, that results in a low failure rate (\<1% per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire study period, and for 90 days after taking the last dose of study drug. Such methods include: oral hormonal contraception (combined estrogen/ progestogen, or progestogen-only) associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal ligation, vasectomized partner, or true sexual abstinence in line with the preferred and usual lifestyle of the participant. Highly effective contraception should always be combined with an additional barrier method (eg, diaphragm, with spermicide). The same criteria are applicable to male participants involved in this clinical trial if they have a partner of childbirth potential, and male participants must always use a condom. * Participants with BRAF-mutant tumors must have been treated with a BRAF inhibitor if approved and available in the participant's home country unless the patient is ineligible for treatment with a BRAF inhibitor.
Exclusion criteria
* Absolute neutrophil count (ANC) \<1.5×109/L, platelet count \<100×109/L, or hemoglobin \<9.0 g/dL. Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed; * Serum total bilirubin \>1.5 × the upper limit of normal (ULN). Participants with Gilbert syndrome, bilirubin \<2 X ULN, and normal AST/ALT are eligible; * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 × ULN in participants without hepatic metastases; ALT or AST \>5 × ULN in participants with hepatic metastases; * Serum creatinine \>1.5 × ULN or creatinine clearance \<60 mL/min. Creatinine clearance can either be measured in a 24-hour urine collection or estimated by the Cockroft-Gault equation. * Urine dipstick protein ≥2+ or 24-hour urine protein ≥1.0 g/24-h. Participants with greater than 2+ proteinuria by dipstick must undergo a 24-hour urine collection to assess urine protein level; * Uncontrolled hypertension, defined as: systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg despite optimal medical management. Participants were required to have blood pressure values below both limits. Repeated assessments were permitted; * International Normalized Ratio (INR) \>1.5 x ULN or activated partial thromboplastin time (aPTT) \>1.5 × ULN, unless the patient is currently receiving or intended to receive anticoagulants for prophylactic purposes; * History of, or active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation or fistulas; or any other condition that could, in the investigator's judgment, result in gastrointestinal hemorrhage or perforation; within the 6 months prior to screening; * History or presence of hemorrhage from any other site (eg, hemoptysis or hematemesis) within 2 months prior to screening; * History of a thromboembolic event, including deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial embolism within 6 months prior to screening. * Stroke and/or transient ischemic attack within 12 months prior to screening; * Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular ejection fraction (LVEF) \<50% by echocardiogram; * Mean corrected QT interval using the Fridericia method (QTcF) \>480 msec or any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in a first-degree relative. * Concomitant medications with a known risk of causing QT prolongation and/or Torsades de Pointes. * Systemic anti-neoplastic therapies (except for those described in Exclusion 18) or any investigational therapy within 4 weeks prior to the first dose of study drug, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy and immunotherapy; * Systemic small molecule targeted therapies (eg, tyrosine kinase inhibitors) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug; * Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study drug; * Brachytherapy (i.e., implantation of radioactive seeds) within 60 days prior to the first dose of study drug. * Use of strong inducers or inhibitors of CYP3A4 within 2 weeks (or 5 half-lives, whichever is longer) before the first dose of study drug; * Surgery or invasive procedure (i.e., a procedure that includes a biopsy; central venous catheter placement is allowed) within 60 days prior to the first dose of study drug or unhealed surgical incision; * Any unresolved toxicities from a previous antitumor treatment greater than CTCAE v5.0 Grade 1 (except for alopecia or neurotoxicity grade≤2); * Known human immunodeficiency virus (HIV) infection; * Known history of active viral hepatitis. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Participants with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load. * Clinically uncontrolled active infection requiring IV antibiotics; * Tumor invasion of a large vascular structure, eg, pulmonary artery, superior or inferior vena cava; * Women who are pregnant or lactating; * Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease for 14 days or longer; participants requiring steroids within 4 weeks prior to start of study treatment are excluded; * Other malignancy, except for non-melanoma skin cancer, in situ cervical ca or bladder ca (Tis and T1) that have been adequately treated during the 5 years prior to screening; * Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or any other condition that investigators believe may affect absorption of the investigational product; * Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition (e.g., current alcohol or drug abuse) that investigators suspect may prohibit use of the investigational product, affect interpretation of study results, or put the patient at undue risk of harm based on the investigator's assessment; * Known hypersensitivity to fruquintinib (or placebo) or any of its inactive ingredients including the azo dyes Tartrazine - FD&C Yellow 5 and Sunset yellow FCF - FD&C Yellow 6; * Participants who have received prior fruquintinib; * Live vaccine \<28days before the first dose of study drug(s). Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From date of randomization to death from any cause (up to 22 months) | OS was defined as the time (months) from date of randomization to death from any cause. OS was calculated as (date of death or last known alive - date of randomization + 1)/30.4375. Participants without report of death at the time of analysis will be censored at the date last known alive. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS), as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 | From randomization until the first documentation of objective progression or death, whichever comes first (up to 22 months) | PFS was defined as the time (months) from randomization until the first radiographic documentation of objective progression as assessed by investigator using RECIST v1.1, or death from any cause, whichever comes first. More specifically, PFS was determined using all data until the last evaluable visit prior to or on the date of: (i) radiographic disease progression (PD) per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy other than the study drugs, whichever was earlier. PD was defined as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; and the appearance of one or more new lesions. |
| Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | From randomization until the first documentation of best overall response (up to 22 months) | DCR was defined as percentage of participants achieving a best overall response of confirmed CR, PR, or stable disease (SD) (for at least 7 weeks) per RECIST v1.1, as determined by the investigator. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. |
| Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | From first occurrence of PR or CR until the first documentation progression or death, whichever comes first (up to 22 months | DOR was defined as the time (in months) from the first occurrence of PR or CR by RECIST Version 1.1, until the first date that progressive disease is documented by RECIST Version 1.1, or death, whichever comes first. Only those participants with confirmed responses of CR or PR were included in this analysis. DOR was calculated as (date of death or PD or last assessment - date of first occurrence of confirmed CR or PR + 1)/30.4375. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | From start of study drug administration up to approximately 40 months | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was considered a TEAE if the onset date was on or after the start of study treatment or if the onset date was missing, or if the AE had an onset date before the start of study treatment but worsened in severity after the study treatment until 30 days after the last dose of study treatment or a new treatment of anti-tumor therapy, whichever was earlier. After this period, treatment-related SAEs were also considered as TEAEs. AEs with an unknown/not reported onset date were also included. |
| Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 (Day 21): Predose and 2 hours, Cycle 3 (Day 1): Pre-dose, Cycle 3 (Day 21): Pre-dose and 2 hours, Cycle 5, 7, 9, 11, 13, 15 and 17 (Day 1): Pre-dose (Each cycle = 28 days) | Plasma samples were collected from the participants at the defined time points. Plasma concentrations were measured using a validated, specific, and sensitive liquid chromatography tandem mass spectrometry method. M11 is the active metabolite for the study drug. |
| Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Baseline, Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 and 3 (Day 21): Pre-dose (Each cycle = 28 days) | QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 milliseconds (msec). QTc: QT interval corrected based on the patient's heart rate. QTcF: An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula. QTc = QT/∛(RR) RR = Respiration rate. |
| Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Baseline, Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 and 3 (Day 21): Pre-dose (Each cycle = 28 days) | QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec. QTc: QT interval corrected based on the patient's heart rate. QTcB: An electrocardiographic finding in which the QT interval corrected for heart rate using Bazzett's formula. |
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | From randomization until the first documentation of best overall response (up to 22 months) | ORR was defined as the percentage of participants who achieved a best overall response of confirmed complete response (CR) or partial response (PR), per RECIST v1.1, as determined by the investigator. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). |
| Correlation Between Fruquintinib Exposure (CmaxSS) and Safety Parameters (Any Grade [Gr] and Grade 3+ (Gr3+): Dermatological Toxicity, Proteinuria and Gr Hemorrhage) | Up to 22 months | Model-predicted steady-state maximum plasma concentration (CmaxSS) of fruquintinib based on the assigned dose of fruquintinib were investigated as fruquintinib exposure measure for the safety exposure-response analyses. The correlation between exposure and the probability of experiencing these AEs was evaluated using logistic regression analysis, with the slope serving as the estimate. The safety exposure-response analysis included participants with cancer, and the data of this outcome measure were pooled with data from the following studies as per the planned analysis: 2019-013-GLOB1 (NCT04322539) (N=334), 2009-013-00CH1 (NCT01645215) (N=40), 2012-013-00CH3 (NCT01975077) (N=40), and 2015-013-00US1 (NCT03251378) (N=101). Here, the unit of measure i.e., '1/(ng/mL)', corresponds to the coefficient that describes the relationship between the probability of occurrence of the safety parameter and CmaxSS value. |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score | Baseline, Cycle 2, 3 and 4 (Each cycle=28 days) | EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=Very poor \[worst\] to 7= Excellent \[best\]). Raw scores are standardized and converted into scale scores ranging from 0 to 100. For global health status/QOL scale, higher scores represent better QOL. A negative change from baseline value indicates patient condition worsened. Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale scores was performed by visit (i.e., cycle), using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. |
| Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score | Baseline, Cycle 2, 3 and 4 (Each cycle=28 days) | The EQ-5D-5L is a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score and a general VAS score for health status. EQ-5D VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. The higher the score the better the health status. A negative change from baseline value represents patient condition worsened. Change from baseline in the EQ-5D-5L VAS scores was performed by visit (i.e. cycle), using a REML-based MMRM approach. |
| Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores | Baseline, Cycle 2, 3 and 4 (Each cycle=28 days) | EQ-5D-5L consisted of 2 components: health state profile and optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problem, 2= slight problem, 3= moderate problem, 4= severe problem, and 5= extreme problem. The response levels collected from the EQ-5D-5L five dimensions as a health profile are converted into an EQ-5D-5L index (utility) scores to represent participants' utility value. The range of health utility index score is from -0.285 to 1, where higher value indicates perfect health and a negative value represents a state worse than dead. Change from baseline in EQ-5D-5L health utility index scores was performed by visit (i.e., cycle), using a REML-based MMRM approach. |
| Health Care Resource Utilization: Duration of Hospital Visits by Participants | From start of study drug administration up to 22 months | Duration of hospital visit was calculated as = stop date - start date + 1. Mean and standard deviation data for duration of hospital visits (in days) by participants was reported in this outcome measure. |
| Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed | From start of study drug administration up to 22 months | Number of participants with any concomitant medications prescribed were reported. |
| Correlation Between Fruquintinib Exposure (CminSS) and Efficacy Parameters (OS) | Up to 22 months | Model-predicted steady-state minimum plasma concentrations (CminSS) of fruquintinib based on the starting dose or adjusted for relative dose intensity \[RDI\] were used as the exposure measures in the efficacy exposure-response analyses. The correlation between OS and exposure was estimated using multivariable Cox proportional hazards modeling. OS was analyzed as time-to-event variable using a survival model. The efficacy exposure-response analyses included participants with mCRC and pooled the data from the fruquintinib group of current Study 2019-013-GLOB1 (N=328) and from Cohort B of Study 2015-013-00US1 (NCT03251378) (N=40) as per planned analysis. Here, the unit of measure i.e., '1/(nanogram per milliliter \[ng/mL\])', corresponds to the coefficient that describes the relationship between the probability of survival and CminSS value. |
Countries
Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, United States
Participant flow
Recruitment details
The study was conducted at 124 study sites in the United States, Europe region, Japan, and Australia.
Pre-assignment details
A total of 691 participants were randomized and enrolled in this study.
Participants by arm
| Arm | Count |
|---|---|
| Fruquintinib + BSC Group Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days). | 461 |
| Placebo + BSC Group Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days). | 230 |
| Total | 691 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 0 |
| Overall Study | Death | 411 | 203 |
| Overall Study | Lost to Follow-up | 3 | 1 |
| Overall Study | Other | 6 | 4 |
| Overall Study | Radiological Disease Progression | 6 | 0 |
| Overall Study | Sponsor Decision | 19 | 14 |
| Overall Study | Withdrawal of consent | 14 | 8 |
Baseline characteristics
| Characteristic | Fruquintinib + BSC Group | Total | Placebo + BSC Group |
|---|---|---|---|
| Age, Continuous | 62.2 years STANDARD_DEVIATION 10.41 | 62.2 years STANDARD_DEVIATION 10.16 | 62.4 years STANDARD_DEVIATION 9.67 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 20 Participants | 34 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 405 Participants | 607 Participants | 202 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 36 Participants | 50 Participants | 14 Participants |
| Race/Ethnicity, Customized Race American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Race Asian | 43 Participants | 61 Participants | 18 Participants |
| Race/Ethnicity, Customized Race Black or African American | 13 Participants | 20 Participants | 7 Participants |
| Race/Ethnicity, Customized Race Multiple races | 2 Participants | 2 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Native Hawaiian or Other | 3 Participants | 5 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Not reported/unknown | 28 Participants | 36 Participants | 8 Participants |
| Race/Ethnicity, Customized Race Other | 5 Participants | 7 Participants | 2 Participants |
| Race/Ethnicity, Customized Race White | 367 Participants | 559 Participants | 192 Participants |
| Sex: Female, Male Female | 216 Participants | 306 Participants | 90 Participants |
| Sex: Female, Male Male | 245 Participants | 385 Participants | 140 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 411 / 461 | 203 / 230 |
| other Total, other adverse events | 446 / 456 | 205 / 230 |
| serious Total, serious adverse events | 173 / 456 | 88 / 230 |
Outcome results
Primary
Overall Survival (OS)
OS was defined as the time (months) from date of randomization to death from any cause. OS was calculated as (date of death or last known alive - date of randomization + 1)/30.4375. Participants without report of death at the time of analysis will be censored at the date last known alive.
Time frame: From date of randomization to death from any cause (up to 22 months)
Population: ITT population included all randomized participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fruquintinib + BSC Group | Overall Survival (OS) | 7.4 months |
| Placebo + BSC Group | Overall Survival (OS) | 4.8 months |
p-value: <0.00195% CI: [0.549, 0.8]stratified log-rank test
Secondary
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score
EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=Very poor \[worst\] to 7= Excellent \[best\]). Raw scores are standardized and converted into scale scores ranging from 0 to 100. For global health status/QOL scale, higher scores represent better QOL. A negative change from baseline value indicates patient condition worsened. Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale scores was performed by visit (i.e., cycle), using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach.
Time frame: Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)
Population: ITT population included all randomized participants. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure and Number analyzed signifies those participants who were evaluable at the specified timepoints.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fruquintinib + BSC Group | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score | Cycle 2 | -2.1 score on a scale | Standard Error 1.59 |
| Fruquintinib + BSC Group | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score | Cycle 3 | -4.5 score on a scale | Standard Error 1.69 |
| Fruquintinib + BSC Group | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score | Cycle 4 | -4.2 score on a scale | Standard Error 1.76 |
| Placebo + BSC Group | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score | Cycle 2 | -3.7 score on a scale | Standard Error 1.95 |
| Placebo + BSC Group | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score | Cycle 3 | -6.1 score on a scale | Standard Error 2.54 |
| Placebo + BSC Group | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score | Cycle 4 | -2.1 score on a scale | Standard Error 3.03 |
Secondary
Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores
EQ-5D-5L consisted of 2 components: health state profile and optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problem, 2= slight problem, 3= moderate problem, 4= severe problem, and 5= extreme problem. The response levels collected from the EQ-5D-5L five dimensions as a health profile are converted into an EQ-5D-5L index (utility) scores to represent participants' utility value. The range of health utility index score is from -0.285 to 1, where higher value indicates perfect health and a negative value represents a state worse than dead. Change from baseline in EQ-5D-5L health utility index scores was performed by visit (i.e., cycle), using a REML-based MMRM approach.
Time frame: Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)
Population: ITT population included all randomized participants. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure and Number analyzed signifies those participants who were evaluable at the specified categories.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fruquintinib + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores | Cycle 2 | 0.0 score on a scale | Standard Error 0.01 |
| Fruquintinib + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores | Cycle 3 | 0.0 score on a scale | Standard Error 0.01 |
| Fruquintinib + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores | Cycle 4 | -0.1 score on a scale | Standard Error 0.02 |
| Placebo + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores | Cycle 2 | 0.0 score on a scale | Standard Error 0.02 |
| Placebo + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores | Cycle 3 | 0.0 score on a scale | Standard Error 0.02 |
| Placebo + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores | Cycle 4 | 0.0 score on a scale | Standard Error 0.03 |
Secondary
Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score
The EQ-5D-5L is a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score and a general VAS score for health status. EQ-5D VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. The higher the score the better the health status. A negative change from baseline value represents patient condition worsened. Change from baseline in the EQ-5D-5L VAS scores was performed by visit (i.e. cycle), using a REML-based MMRM approach.
Time frame: Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)
Population: ITT population included all randomized participants. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure and Number analyzed signifies those participants who were evaluable at the specified categories.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fruquintinib + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score | Cycle 2 | -0.3 score on a scale | Standard Error 1.38 |
| Fruquintinib + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score | Cycle 3 | -1.1 score on a scale | Standard Error 1.48 |
| Fruquintinib + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score | Cycle 4 | -4.0 score on a scale | Standard Error 1.59 |
| Placebo + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score | Cycle 2 | -0.9 score on a scale | Standard Error 1.69 |
| Placebo + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score | Cycle 3 | -2.5 score on a scale | Standard Error 2.22 |
| Placebo + BSC Group | Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score | Cycle 4 | -2.1 score on a scale | Standard Error 2.79 |
Secondary
Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula
QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec. QTc: QT interval corrected based on the patient's heart rate. QTcB: An electrocardiographic finding in which the QT interval corrected for heart rate using Bazzett's formula.
Time frame: Baseline, Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 and 3 (Day 21): Pre-dose (Each cycle = 28 days)
Population: SP included all randomized participants who received at least 1 dose of study drug. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure and Number analyzed signifies those participants who were evaluable at the specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 3 hours | -0.9 msec | Standard Deviation 24.47 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 2 hours | 1.6 msec | Standard Deviation 42.28 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 2 hours | -2.0 msec | Standard Deviation 23.95 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 3 hours | 1.2 msec | Standard Deviation 25.41 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 4 hours | -1.9 msec | Standard Deviation 24.47 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 4 hours | 0.2 msec | Standard Deviation 25.91 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - Pre-dose | 3.9 msec | Standard Deviation 49.99 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 2 Day 21 - 2 hours | 1.7 msec | Standard Deviation 40.61 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 1 hour | -3.1 msec | Standard Deviation 23.95 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 3 Day 21 - 2 hours | 4.2 msec | Standard Deviation 72.35 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 1 hour | -1.3 msec | Standard Deviation 25.6 |
| Fruquintinib + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - Pre-dose | 2.9 msec | Standard Deviation 39.49 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 4 hours | 2.4 msec | Standard Deviation 20.11 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - Pre-dose | 0.3 msec | Standard Deviation 20.55 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 1 hour | 1.9 msec | Standard Deviation 20.11 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 2 hours | 1.9 msec | Standard Deviation 20.11 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 1 - 3 hours | 3.9 msec | Standard Deviation 19.75 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - Pre-dose | 5.0 msec | Standard Deviation 50.43 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 1 hour | 0.9 msec | Standard Deviation 20.48 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 2 hours | 4.3 msec | Standard Deviation 19.57 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 3 hours | 2.9 msec | Standard Deviation 18.29 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 1 Day 21 - 4 hours | 2.8 msec | Standard Deviation 20.13 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 2 Day 21 - 2 hours | 5.9 msec | Standard Deviation 24.96 |
| Placebo + BSC Group | Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula | Cycle 3 Day 21 - 2 hours | 1.6 msec | Standard Deviation 22.06 |
Secondary
Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula
QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 milliseconds (msec). QTc: QT interval corrected based on the patient's heart rate. QTcF: An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula. QTc = QT/∛(RR) RR = Respiration rate.
Time frame: Baseline, Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 and 3 (Day 21): Pre-dose (Each cycle = 28 days)
Population: SP included all randomized participants who received at least 1 dose of study drug. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure and number analyzed signifies those participants who were evaluable at the specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 3 hours | 5.9 millisecond (msec) | Standard Deviation 19.46 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - Pre-dose | 1.9 millisecond (msec) | Standard Deviation 21.33 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 1 hour | -0.1 millisecond (msec) | Standard Deviation 19.6 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 2 hours | 1.9 millisecond (msec) | Standard Deviation 22.58 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 3 hours | 2.6 millisecond (msec) | Standard Deviation 19.77 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 4 hours | 1.2 millisecond (msec) | Standard Deviation 20.48 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - Pre-dose | 3.2 millisecond (msec) | Standard Deviation 20.94 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 1 hour | 4.0 millisecond (msec) | Standard Deviation 19.56 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 2 hours | 5.0 millisecond (msec) | Standard Deviation 20.06 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 4 hours | 3.9 millisecond (msec) | Standard Deviation 20.98 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 2 Day 21 - 2 hours | 1.4 millisecond (msec) | Standard Deviation 22.41 |
| Fruquintinib + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 3 Day 21 - 2 hours | 2.6 millisecond (msec) | Standard Deviation 31.61 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 2 Day 21 - 2 hours | 4.9 millisecond (msec) | Standard Deviation 24.28 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 2 hours | 2.8 millisecond (msec) | Standard Deviation 18.23 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - Pre-dose | -2.2 millisecond (msec) | Standard Deviation 20.31 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - Pre-dose | 0.1 millisecond (msec) | Standard Deviation 17.95 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 4 hours | -0.6 millisecond (msec) | Standard Deviation 18.13 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 1 hour | 2.5 millisecond (msec) | Standard Deviation 19.7 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 1 hour | -0.2 millisecond (msec) | Standard Deviation 16.77 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 2 hours | 3.5 millisecond (msec) | Standard Deviation 20.13 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 3 Day 21 - 2 hours | 2.0 millisecond (msec) | Standard Deviation 20.08 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 3 hours | 3.3 millisecond (msec) | Standard Deviation 18.03 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 21 - 3 hours | 0.2 millisecond (msec) | Standard Deviation 14.7 |
| Placebo + BSC Group | Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula | Cycle 1 Day 1 - 4 hours | 0.9 millisecond (msec) | Standard Deviation 17.66 |
Secondary
Correlation Between Fruquintinib Exposure (CmaxSS) and Safety Parameters (Any Grade [Gr] and Grade 3+ (Gr3+): Dermatological Toxicity, Proteinuria and Gr Hemorrhage)
Model-predicted steady-state maximum plasma concentration (CmaxSS) of fruquintinib based on the assigned dose of fruquintinib were investigated as fruquintinib exposure measure for the safety exposure-response analyses. The correlation between exposure and the probability of experiencing these AEs was evaluated using logistic regression analysis, with the slope serving as the estimate. The safety exposure-response analysis included participants with cancer, and the data of this outcome measure were pooled with data from the following studies as per the planned analysis: 2019-013-GLOB1 (NCT04322539) (N=334), 2009-013-00CH1 (NCT01645215) (N=40), 2012-013-00CH3 (NCT01975077) (N=40), and 2015-013-00US1 (NCT03251378) (N=101). Here, the unit of measure i.e., '1/(ng/mL)', corresponds to the coefficient that describes the relationship between the probability of occurrence of the safety parameter and CmaxSS value.
Time frame: Up to 22 months
Population: Safety exposure-response analyses included participants who were evaluable for population PK analysis and therefore had PK parameter estimates to enable estimation of fruquintinib exposure and evaluated for parameter/endpoint in question. Here, overall number of participants analyzed signified those participants who were evaluable for this outcome measure. The population for this measure included participants from 2019-013-GLOB1, 2009-013-00CH1, 2012-013-00CH3, and 2015-013-00US1.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fruquintinib + BSC Group | Correlation Between Fruquintinib Exposure (CmaxSS) and Safety Parameters (Any Grade [Gr] and Grade 3+ (Gr3+): Dermatological Toxicity, Proteinuria and Gr Hemorrhage) | CmaxSS Coefficient for Gr Dermatological toxicity for Exposure-Response Analyses | 0.00134 1/(ng/mL) |
| Fruquintinib + BSC Group | Correlation Between Fruquintinib Exposure (CmaxSS) and Safety Parameters (Any Grade [Gr] and Grade 3+ (Gr3+): Dermatological Toxicity, Proteinuria and Gr Hemorrhage) | CmaxSS Coefficient for Gr3+ Dermatological Toxicity for Exposure-Response Analyses | 0.00411 1/(ng/mL) |
| Fruquintinib + BSC Group | Correlation Between Fruquintinib Exposure (CmaxSS) and Safety Parameters (Any Grade [Gr] and Grade 3+ (Gr3+): Dermatological Toxicity, Proteinuria and Gr Hemorrhage) | CmaxSS Coefficient for Gr Proteinuria for Exposure-Response Analyses | -0.00101 1/(ng/mL) |
| Fruquintinib + BSC Group | Correlation Between Fruquintinib Exposure (CmaxSS) and Safety Parameters (Any Grade [Gr] and Grade 3+ (Gr3+): Dermatological Toxicity, Proteinuria and Gr Hemorrhage) | CmaxSS Coefficient for Gr3+ Proteinuria for Exposure-Response Analyses | 0.00143 1/(ng/mL) |
| Fruquintinib + BSC Group | Correlation Between Fruquintinib Exposure (CmaxSS) and Safety Parameters (Any Grade [Gr] and Grade 3+ (Gr3+): Dermatological Toxicity, Proteinuria and Gr Hemorrhage) | CmaxSS Coefficient for Gr Hemorrhage for Exposure-Response Analyses | 0.00180 1/(ng/mL) |
Comparison: CmaxSS for Gr Dermatological toxicity for Exposure-Response Analyses.p-value: 0.265Wald test
Comparison: CmaxSS for Gr3+ Dermatological Toxicity for Exposure-Response Analyses.p-value: 0.0159Wald test
Comparison: CmaxSS for Gr Proteinuria for Exposure-Response Analyses.p-value: 0.484Wald test
Comparison: CmaxSS for Gr3+ Proteinuria for Exposure-Response Analyses.p-value: 0.642Wald test
Comparison: CmaxSS for Gr Hemorrhage for Exposure-Response Analyses.p-value: 0.166Wald test
Secondary
Correlation Between Fruquintinib Exposure (CminSS) and Efficacy Parameters (OS)
Model-predicted steady-state minimum plasma concentrations (CminSS) of fruquintinib based on the starting dose or adjusted for relative dose intensity \[RDI\] were used as the exposure measures in the efficacy exposure-response analyses. The correlation between OS and exposure was estimated using multivariable Cox proportional hazards modeling. OS was analyzed as time-to-event variable using a survival model. The efficacy exposure-response analyses included participants with mCRC and pooled the data from the fruquintinib group of current Study 2019-013-GLOB1 (N=328) and from Cohort B of Study 2015-013-00US1 (NCT03251378) (N=40) as per planned analysis. Here, the unit of measure i.e., '1/(nanogram per milliliter \[ng/mL\])', corresponds to the coefficient that describes the relationship between the probability of survival and CminSS value.
Time frame: Up to 22 months
Population: The efficacy exposure-response analyses included participants who were evaluable for the population PK analysis and therefore had PK parameter estimates to enable estimation of fruquintinib exposure and evaluated for the parameter/endpoint in question. Here, overall number of participants analyzed signified those participants who were evaluable for this outcome measure. The population for this measure included participants from both studies 2015-013-00US1 and the current study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fruquintinib + BSC Group | Correlation Between Fruquintinib Exposure (CminSS) and Efficacy Parameters (OS) | CminSS Coefficient Based on the Starting Dose for OS Exposure-Response Analyses | 0.00193 1/(ng/mL) |
| Fruquintinib + BSC Group | Correlation Between Fruquintinib Exposure (CminSS) and Efficacy Parameters (OS) | CminSS Coefficient Based on the Adjusted RDI for OS Exposure-Response Analyses | 0.000407 1/(ng/mL) |
Comparison: CminSS Based on the Starting Dose for OS Exposure-Response Analysesp-value: 0.06Wald test
Comparison: CminSS Based on the Adjusted RDI for OS Exposure-Response Analysesp-value: 0.8065Wald test
Secondary
Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
DCR was defined as percentage of participants achieving a best overall response of confirmed CR, PR, or stable disease (SD) (for at least 7 weeks) per RECIST v1.1, as determined by the investigator. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
Time frame: From randomization until the first documentation of best overall response (up to 22 months)
Population: ITT population included all randomized participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fruquintinib + BSC Group | Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 55.5 percentage of participants |
| Placebo + BSC Group | Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 16.1 percentage of participants |
p-value: <0.00195% CI: [32.8, 46]Cochran-Mantel-Haenszel
Secondary
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
DOR was defined as the time (in months) from the first occurrence of PR or CR by RECIST Version 1.1, until the first date that progressive disease is documented by RECIST Version 1.1, or death, whichever comes first. Only those participants with confirmed responses of CR or PR were included in this analysis. DOR was calculated as (date of death or PD or last assessment - date of first occurrence of confirmed CR or PR + 1)/30.4375.
Time frame: From first occurrence of PR or CR until the first documentation progression or death, whichever comes first (up to 22 months
Population: Analysis was performed on subset of participants who had a response. Here, '0' in 'overall number of participants analyzed represents that DOR could only be analyzed in participants who achieved a response. As no participant in the Placebo Plus BSC Group cohort achieved any response, no DOR is available.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fruquintinib + BSC Group | Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 10.7 months |
Secondary
Health Care Resource Utilization: Duration of Hospital Visits by Participants
Duration of hospital visit was calculated as = stop date - start date + 1. Mean and standard deviation data for duration of hospital visits (in days) by participants was reported in this outcome measure.
Time frame: From start of study drug administration up to 22 months
Population: ITT population included all randomized participants.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fruquintinib + BSC Group | Health Care Resource Utilization: Duration of Hospital Visits by Participants | 3.3 days per visit | Standard Deviation 6.81 |
| Placebo + BSC Group | Health Care Resource Utilization: Duration of Hospital Visits by Participants | 4.4 days per visit | Standard Deviation 7.53 |
Secondary
Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed
Number of participants with any concomitant medications prescribed were reported.
Time frame: From start of study drug administration up to 22 months
Population: ITT population included all randomized participants.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Fruquintinib + BSC Group | Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed | 116 Participants |
| Placebo + BSC Group | Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed | 63 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was considered a TEAE if the onset date was on or after the start of study treatment or if the onset date was missing, or if the AE had an onset date before the start of study treatment but worsened in severity after the study treatment until 30 days after the last dose of study treatment or a new treatment of anti-tumor therapy, whichever was earlier. After this period, treatment-related SAEs were also considered as TEAEs. AEs with an unknown/not reported onset date were also included.
Time frame: From start of study drug administration up to approximately 40 months
Population: SP included all randomized participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Fruquintinib + BSC Group | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | Participants with TEAEs | 451 Participants |
| Fruquintinib + BSC Group | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | Participants with Serious TEAEs | 173 Participants |
| Placebo + BSC Group | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | Participants with Serious TEAEs | 88 Participants |
| Placebo + BSC Group | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | Participants with TEAEs | 214 Participants |
Secondary
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
ORR was defined as the percentage of participants who achieved a best overall response of confirmed complete response (CR) or partial response (PR), per RECIST v1.1, as determined by the investigator. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
Time frame: From randomization until the first documentation of best overall response (up to 22 months)
Population: ITT population included all randomized participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fruquintinib + BSC Group | Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 1.5 percentage of participants |
| Placebo + BSC Group | Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 0 percentage of participants |
p-value: 0.05995% CI: [0.4, 2.7]Cochran-Mantel-Haenszel
Secondary
Observed Plasma Concentrations of Fruquintinib and Metabolite M11
Plasma samples were collected from the participants at the defined time points. Plasma concentrations were measured using a validated, specific, and sensitive liquid chromatography tandem mass spectrometry method. M11 is the active metabolite for the study drug.
Time frame: Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 (Day 21): Predose and 2 hours, Cycle 3 (Day 1): Pre-dose, Cycle 3 (Day 21): Pre-dose and 2 hours, Cycle 5, 7, 9, 11, 13, 15 and 17 (Day 1): Pre-dose (Each cycle = 28 days)
Population: PK population was used for tabulation of fruquintinib and M11 concentrations from PK plasma samples collected from the Fruquintinib + BSC Group. PK samples for the Placebo + BSC Group were not analyzed. Here, Overall Number of Participants Analyzed signifies those participants in the Fruquintinib + BSC Group who were evaluable for this outcome measure and number analyzed signifies those participants who were evaluable at the specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - Pre-dose (Plasma Concentrations of Fruquintinib) | 2.90 nanogram/milliliter (ng/mL) | Standard Deviation 19.9 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - Pre-dose (Plasma Concentrations of M11) | 0.585 nanogram/milliliter (ng/mL) | Standard Deviation 6.61 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 1 hour (Plasma Concentrations of Fruquintinib) | 59.9 nanogram/milliliter (ng/mL) | Standard Deviation 51 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 1 hour (Plasma Concentrations of M11) | 1.06 nanogram/milliliter (ng/mL) | Standard Deviation 8.36 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 2 hours (Plasma Concentrations of Fruquintinib) | 91.5 nanogram/milliliter (ng/mL) | Standard Deviation 48.2 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 2 hours (Plasma Concentrations of M11) | 1.03 nanogram/milliliter (ng/mL) | Standard Deviation 6.81 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 3 hours (Plasma Concentrations of Fruquintinib) | 98.5 nanogram/milliliter (ng/mL) | Standard Deviation 47.1 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 3 hours (Plasma Concentrations of M11) | 1.96 nanogram/milliliter (ng/mL) | Standard Deviation 9.51 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 4 hours (Plasma Concentrations of Fruquintinib) | 99.7 nanogram/milliliter (ng/mL) | Standard Deviation 44.6 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 1 - 4 hours (Plasma Concentrations of M11) | 2.71 nanogram/milliliter (ng/mL) | Standard Deviation 10.7 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - Pre-dose (Plasma Concentrations of Fruquintinib) | 219 nanogram/milliliter (ng/mL) | Standard Deviation 82.6 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - Pre-dose (Plasma Concentrations of M11) | 94.5 nanogram/milliliter (ng/mL) | Standard Deviation 52.6 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - 1 hour (Plasma Concentrations of Fruquintinib) | 255 nanogram/milliliter (ng/mL) | Standard Deviation 101 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - 1 hour (Plasma Concentrations of M11) | 92.0 nanogram/milliliter (ng/mL) | Standard Deviation 54.3 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - 2 hours (Plasma Concentrations of Fruquintinib) | 279 nanogram/milliliter (ng/mL) | Standard Deviation 91.6 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - 2 hours (Plasma Concentrations of M11) | 89.9 nanogram/milliliter (ng/mL) | Standard Deviation 49.5 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 -3 hours (Plasma Concentrations of Fruquintinib) | 293 nanogram/milliliter (ng/mL) | Standard Deviation 95.2 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - 3 hours (Plasma Concentrations of M11) | 88.0 nanogram/milliliter (ng/mL) | Standard Deviation 50.4 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - 4 hours (Plasma Concentrations of Fruquintinib) | 294 nanogram/milliliter (ng/mL) | Standard Deviation 88 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 1 Day 21 - 4 hours (Plasma Concentrations of M11) | 89.2 nanogram/milliliter (ng/mL) | Standard Deviation 49 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 2 Day 21 - Predose (Plasma Concentrations of Fruquintinib) | 222 nanogram/milliliter (ng/mL) | Standard Deviation 82 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 2 Day 21 - Predose (Plasma Concentrations of M11) | 97.6 nanogram/milliliter (ng/mL) | Standard Deviation 53.7 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 2 Day 21 - 2 hours (Plasma Concentrations of Fruquintinib) | 284 nanogram/milliliter (ng/mL) | Standard Deviation 95.2 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 2 Day 21 - 2 hours (Plasma Concentrations of M11) | 94.2 nanogram/milliliter (ng/mL) | Standard Deviation 52.8 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 3 Day 1 - Pre-dose (Plasma Concentrations of Fruquintinib) | 16.7 nanogram/milliliter (ng/mL) | Standard Deviation 18.9 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 3 Day 1 - Pre-dose (Plasma Concentrations of M11) | 22.6 nanogram/milliliter (ng/mL) | Standard Deviation 18.2 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 3 Day 21 - Pre-dose (Plasma Concentrations of Fruquintinib) | 212 nanogram/milliliter (ng/mL) | Standard Deviation 74.6 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 3 Day 21 - Pre-dose (Plasma Concentrations of M11) | 90.6 nanogram/milliliter (ng/mL) | Standard Deviation 54.1 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 3 Day 21 - 2 hours (Plasma Concentrations of Fruquintinib) | 275 nanogram/milliliter (ng/mL) | Standard Deviation 78.6 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 3 Day 21 - 2 hours (Plasma Concentrations of M11) | 92.8 nanogram/milliliter (ng/mL) | Standard Deviation 54.2 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 5 Day 1 - Pre-Dose (Plasma Concentrations of Fruquintinib) | 16.9 nanogram/milliliter (ng/mL) | Standard Deviation 20.5 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 5 Day 1 - Pre-Dose (Plasma Concentrations of M11) | 23.2 nanogram/milliliter (ng/mL) | Standard Deviation 20.9 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 7 Day 1 - Pre-Dose (Plasma Concentrations of Fruquintinib | 18.2 nanogram/milliliter (ng/mL) | Standard Deviation 33 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 7 Day 1 - Pre-Dose (Plasma Concentrations of M11) | 20.1 nanogram/milliliter (ng/mL) | Standard Deviation 12.1 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 9 Day 1 - Pre-Dose (Plasma Concentrations of Fruquintinib) | 12.2 nanogram/milliliter (ng/mL) | Standard Deviation 12.6 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 9 Day 1 - Pre-Dose (Plasma Concentrations of M11) | 19.1 nanogram/milliliter (ng/mL) | Standard Deviation 17.1 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 11 Day 1 - Pre-Dose (Plasma Concentrations of Fruquintinib) | 13.4 nanogram/milliliter (ng/mL) | Standard Deviation 13.4 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 11 Day 1 - Pre-Dose (Plasma Concentrations of M11) | 17.1 nanogram/milliliter (ng/mL) | Standard Deviation 15.3 |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 13 Day 1 - Pre-Dose (Plasma Concentrations of Fruquintinib) | 15.4 nanogram/milliliter (ng/mL) | — |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 13 Day 1 - Pre-Dose (Plasma Concentrations of M11) | 23.1 nanogram/milliliter (ng/mL) | — |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 15 Day 1 - Pre-Dose (Plasma Concentrations of Fruquintinib) | 10.8 nanogram/milliliter (ng/mL) | — |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 15 Day 1 - Pre-Dose (Plasma Concentrations of M11) | 19.2 nanogram/milliliter (ng/mL) | — |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 17 Day 1 - Pre-Dose (Plasma Concentrations of Fruquintinib) | 10.6 nanogram/milliliter (ng/mL) | — |
| Fruquintinib + BSC Group | Observed Plasma Concentrations of Fruquintinib and Metabolite M11 | Cycle 17 Day 1 - Pre-Dose (Plasma Concentrations of M11) | 15.2 nanogram/milliliter (ng/mL) | — |
Secondary
Progression Free Survival (PFS), as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
PFS was defined as the time (months) from randomization until the first radiographic documentation of objective progression as assessed by investigator using RECIST v1.1, or death from any cause, whichever comes first. More specifically, PFS was determined using all data until the last evaluable visit prior to or on the date of: (i) radiographic disease progression (PD) per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy other than the study drugs, whichever was earlier. PD was defined as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; and the appearance of one or more new lesions.
Time frame: From randomization until the first documentation of objective progression or death, whichever comes first (up to 22 months)
Population: ITT population included all randomized participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fruquintinib + BSC Group | Progression Free Survival (PFS), as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 | 3.7 months |
| Placebo + BSC Group | Progression Free Survival (PFS), as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 | 1.8 months |
p-value: <0.00195% CI: [0.267, 0.386]stratified log-rank test